Skip to content Skip to footer
Subscribe Now
TOP 20

Top 20 R&D Spending Biopharma Companies of 2025  

Shots:  Research and Development (R&D) serves as the driving force behind groundbreaking therapeutic innovations, laying the foundation for advancements that transform patient health and overall well-being  The global Top 20 pharmaceutical leaders spent ~$180B in 2024, with Merck & Co. contributing the most with a whopping $17.93B, followed by Johnson & Johnson ($17.23B) and Roche…
2 days ago

Read more

NEWS

Boehringer Ingelheim Joins Forces with Palatin to Develop Novel Therapies for Retinal Diseases

Shots: BI has entered into a global research collaboration and licensing agreement with Palatin Technologies to develop novel melanocortin receptor agonist for retinal diseases As per the deal, Palatin is eligible for ~$327.6M (€280M) in upfront, development, regulatory, & commercial milestone payments, along with tiered royalties on net sales Collaboration strengthens Boehringer’s retinal pipeline by…
4 days ago

Read more

NEWS

BI Collaborates with Re-Vana Therapeutics to Develop Long-Acting Therapeutics for Eye Diseases

Shots: BI & Re-Vana Therapeutics have entered into a strategic collaboration & license agreement to develop extended-release therapies for eye diseases As per the deal, BI will obtain target exclusivity, while Re-Vana will receive over $1B in total potential deal value for the initial 3 targets, incl. upfront, development, regulatory, & commercial milestones, plus royalties…
July 29, 2025

Read more

Viverita and Boehringer Ingelheim
NEWS

ViVerita Therapeutics Collaborates with Boehringer Ingelheim to Accelerate Discovery of Novel Therapeutic Targets in Oncology

Shots: ViVerita Therapeutics & BI have entered into a strategic research collaboration to accelerate discovery & validation of novel cancer targets. Although financial terms of the deal were not disclosed As per the deal, ViVerita will utilize its in vivo CRISPR discovery platform to study selected potential targets from BI, evaluating their functions in physiologically relevant…
May 8, 2025

Read more

Cue Biopharma & Boehringer Ingelheim
NEWS

Cue Biopharma Collaborates with Boehringer Ingelheim to Develop B cell-Targeting Bispecifics for Autoimmune and Inflammatory Diseases

Shots: BI & Cue Biopharma have entered into a multi-year strategic research & license agreement to develop & commercialize CUE-501 for autoimmune diseases, with the potential to expand into other B cell-targeting bispecifics using Cue’s Immuno-STAT platform As per the deal, Cue Biopharma will receive a $12M upfront & ~$345M in research, development, & commercial…
April 15, 2025

Read more

Boehringer Ingelheim
NEWS

Boehringer Ingelheim Introduces Vaxxitek HVT+IBD+H5 Vaccine Against Marek’s Disease, Infectious Bursal Disease and H5 Avian Influenza

Shots: BI has launched Vaxxitek HVT+IBD+H5, a trivalent poultry vaccine against marek’s disease, infectious bursal disease & H5 avian influenza; commercially available in Egypt by Feb 2025 Trivalent vaccine uses BI's COBRA tech to create unique antigen for protection against prevalent H5 clades & is administered at the hatchery for early chick protection to avoid…
February 25, 2025

Read more

Load more